Related references
Note: Only part of the references are listed.Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
S. Vincent Rajkumar et al.
BLOOD (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics
Najoua Lalaoui et al.
CANCER CELL (2016)
Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study
Tasnim Chagtai et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A. Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
beta 2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis
Lucas K. Smith et al.
NATURE MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
Brian A. Walker et al.
NATURE COMMUNICATIONS (2015)
A Molecular Diagnostic Approach Able to Detect the Recurrent Genetic Prognostic Factors Typical of Presenting Myeloma
Eileen M. Boyle et al.
GENES CHROMOSOMES & CANCER (2015)
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
Jeffrey R. Sawyer et al.
BLOOD (2014)
Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
Laura Tornatore et al.
CANCER CELL (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
An overview of the progress in the treatment of multiple myeloma
Robert A. Kyle et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB
Yulia N. Demchenko et al.
ONCOTARGET (2014)
Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
Gareth J. Morgan et al.
CLINICAL CANCER RESEARCH (2013)
Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma
Scott Van Wier et al.
HAEMATOLOGICA (2013)
A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR
M. F. Kaiser et al.
LEUKEMIA (2013)
NF-κB, the first quarter-century: remarkable progress and outstanding questions
Matthew S. Hayden et al.
GENES & DEVELOPMENT (2012)
A20 and CYLD Do Not Share Significant Overlapping Functions during B Cell Development and Activation
Yuanyuan Chu et al.
JOURNAL OF IMMUNOLOGY (2012)
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
K. D. Boyd et al.
LEUKEMIA (2012)
The Clinical Impact and Molecular Biology of del(17p) in Multiple Myeloma Treated with Conventional or Thalidomide-Based Therapy
Kevin D. Boyd et al.
GENES CHROMOSOMES & CANCER (2011)
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J. Morgan et al.
LANCET ONCOLOGY (2011)
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Brian A. Walker et al.
BLOOD (2010)
Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome
Nicholas J. Dickens et al.
CLINICAL CANCER RESEARCH (2010)
Evaluation of Multiplex Ligation-Dependent Probe Amplification as a Method for the Detection of Copy Number Abnormalities in B-Cell Precursor Acute Lymphoblastic Leukemia
C. J. Schwab et al.
GENES CHROMOSOMES & CANCER (2010)
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance
Fiona M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Prognostic Significance of Copy-Number Alterations in Multiple Myeloma
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
R. Fonseca et al.
LEUKEMIA (2006)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
JJ Keats et al.
BLOOD (2003)
Hypodiploidy is a major prognostic factor in multiple myeloma
NV Smadja et al.
BLOOD (2001)
Share Paper
